Latest Innovation News

Black Canyon Limited’s Phase 2 drilling at the Wandanya Project confirms extensive high-grade manganese and iron mineralisation, revealing significant scale and promising exploration upside.

Aquirian Limited has secured $5 million in fresh capital to upgrade its Wubin emulsion facility and accelerate commercialization of its innovative Collar Keeper® technology, alongside a new $1.5 million tolling contract.

Proteomics International has achieved a major milestone with the first worldwide patent granted in Japan for its PromarkerEndo blood test, designed to diagnose endometriosis early and accurately.

Assetora Australia Limited has been officially appointed as the Responsible Entity of the DomaCom Fund, lifting previous restrictions and paving the way for renewed investment activity and secondary market trading.

Papyrus Australia has successfully expanded its banana fibre technology to produce boards and flat paper products, while advancing a promising joint venture in Vietnam for high-volume production.

Papyrus Australia reported a modest net operating cash outflow of $39,000 for May 2025, maintaining a solid cash position supported by available loan facilities that extend its funding runway to over 16 months.

Anagenics Limited’s licensed brand Bouf Haircare is outperforming expectations with strong early sales and promising royalty returns, signaling robust growth potential for the company’s intellectual property portfolio.

Oceania Holdings Limited showcased robust operational progress and a strategic pivot towards portfolio modernization at its 2025 Annual Meeting, while announcing a new cost savings program and withholding its final dividend for FY25.

Atomo Diagnostics has successfully closed a Share Purchase Plan and secured shareholder approval for a Tranche 2 Placement, raising a combined $1.53 million to support its ongoing operations.

Coventry Group Limited has appointed Nik Alpert as Acting Group CEO, while announcing the retirement of CFO Rod Jackson and the upcoming appointment of Patrick Maloney as his successor.

NeuroScientific Biopharmaceuticals has completed its acquisition of StemSmart stem cell technology, setting the stage for a focused clinical push in treating fistulising Crohn’s disease. The company also refreshed its board and raised $7.5 million to support this next phase.

PYC Therapeutics has announced promising pre-clinical results for its RNA-based drug candidate PYC-002, targeting the genetic root of Phelan-McDermid Syndrome, with clinical trials expected to begin in 2026.